{
    "root": "cbedd906-24b6-4a83-875d-3b9e81cf3e46",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin",
    "value": "20240501",
    "ingredients": [
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        }
    ],
    "indications": {
        "text": "adults pediatric patients upper respiratory tract infections ear , nose , throat : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcus species . ( \u03b1- \u03b2-hemolytic isolates ) , streptococcus pneumoniae , staphylococcus spp . , haemophilus influenzae . infections genitourinary tract : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates escherichia coli , proteus mirabilis , enterococcus faecalis . infections skin skin structure : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcus spp . ( \u03b1- \u03b2-hemolytic isolates ) , staphylococcus spp . , e. coli . infections lower respiratory tract : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcus spp . ( \u03b1- \u03b2-hemolytic isolates ) , s. pneumoniae , staphylococcus spp . , h. influenzae . adult patients helicobacter pylori infection duodenal ulcer disease : triple therapy helicobacter pylori ( h. pylori ) clarithromycin lansoprazole : amoxicillin , combination clarithromycin plus lansoprazole triple therapy , indicated treatment patients h. pylori infection duodenal ulcer disease ( active 1-year history duodenal ulcer ) eradicate h. pylori . eradication h. pylori shown reduce risk duodenal ulcer recurrence . dual therapy h. pylori lansoprazole : amoxicillin , combination lansoprazole delayed-release capsules dual therapy , indicated treatment patients h. pylori infection duodenal ulcer disease ( active 1-year history duodenal ulcer ) either allergic intolerant clarithromycin resistance clarithromycin known suspected . ( clarithromycin package insert , microbiology . ) eradication h. pylori shown reduce risk duodenal ulcer recurrence . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin antibacterial drugs , amoxicillin used treat infections proven strongly suspected caused bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [
            {
                "text": "helicobacter pylori infection (DOID:3686)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3686"
            },
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults , 750 1750 mg/day divided doses every 8 12 hours . pediatric patients 3 months age , 20 45 mg/kg/day divided doses every 8 12 hours . refer full prescribing information dosing regimens . ( 2.2 , 2.3 ) upper dose neonates infants aged 3 months younger 30 mg/kg/day divided every 12 hours . ( 2.3 ) dosing h. pylori infection ( adults ) : triple therapy : 1 gram amoxicillin , 500 mg clarithromycin , 30 mg lansoprazole , given twice daily ( every 12 hours ) 14 days . dual therapy : 1 gram amoxicillin 30 mg lansoprazole , given three times daily ( every 8 hours ) 14 days . ( 2.4 ) reduce dose patients severe renal impairment ( gfr greater 30 ml/min ) . ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "amoxicillin tablets , usp : 500 mg : tablet contains 500 mg amoxicillin , usp trihydrate . film-coated , capsule-shaped , off-white , tablet debossed \u201c 93 \u201d one side \u201c 2263 \u201d side . available bottles 100 ( ndc 0093-2263-01 ) tablets . 875 mg : tablet contains 875 mg amoxicillin , usp trihydrate . film-coated , capsule-shaped , off-white tablet scored one side , debossed \u201c 93 \u201d one side score \u201c 2264 \u201d side score . available bottles 100 ( ndc 0093-2264-01 ) tablets . amoxicillin oral suspension , usp : 200 mg/5 ml : 5 ml reconstituted pink , fruit gum flavored suspension contains 200 mg amoxicillin , usp trihydrate . available bottles 50 ml ( ndc 0093-4160-76 ) , 75 ml ( ndc 0093-4160-78 ) , 100 ml ( ndc 0093-4160-73 ) . 250 mg/5 ml : 5 ml reconstituted mixed berry flavored suspension contains 250 mg amoxicillin , usp trihydrate . available bottles 80 ml ( ndc 0093-4155-79 ) , 100 ml ( ndc 0093-4155-73 ) , 150 ml ( ndc 0093-4155-80 ) . 400 mg/5 ml : 5 ml reconstituted pink , fruit gum flavored suspension contains 400 mg amoxicillin , usp trihydrate . available bottles 50 ml ( ndc 0093-4161-76 ) , 75 ml ( ndc 0093-4161-78 ) , 100 ml ( ndc 0093-4161-73 ) . amoxicillin tablets ( chewable ) , usp : 125 mg : white off-white , capsule-shaped tablet , debossed 93 one side 2267 side contain 125 mg amoxicillin , usp trihydrate . available bottles 100 tablets ( ndc 0093-2267-01 ) . 250 mg : white off-white , capsule-shaped tablet , debossed 93 ( partial bisect 9 3 ) one side 2268 side contain 250 mg amoxicillin , usp trihydrate . available bottles 100 tablets ( ndc 0093-2268-01 ) . amoxicillin capsules , usp 250 mg : opaque caramel cap opaque buff body , hard gelatin capsule . printed black \u201c teva \u201d cap \u201c 3107 \u201d body portions capsule contain 250 mg amoxicillin , usp trihydrate . available bottles 100 ( ndc 0093-3107-01 ) 500 ( ndc 0093-3107-05 ) capsules . 500 mg : opaque buff cap opaque buff body , hard gelatin capsules . printed black \u201c teva \u201d cap \u201c 3109 \u201d body portions capsules contain 500 mg amoxicillin , usp trihydrate . available bottles 50 ( ndc 0093-3109-53 ) , 60 ( ndc 0093-3109-06 ) , 100 ( ndc 0093-3109-01 ) 500 ( ndc 0093-3109-05 ) capsules . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . keep medications reach children .",
    "adverseReactions": "amoxicillin contraindicated patients experienced serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin \u03b2-lactam antibacterial drugs ( e.g . , penicillins cephalosporins ) .",
    "indications_original": "Adults and Pediatric Patients\n                  \n                  \n                     \n                        Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of Streptococcus species. (\u03b1- and \u03b2-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae.\n                     \n                        Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis.\n                     \n                        Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of Streptococcus spp. (\u03b1- and \u03b2-hemolytic isolates only), Staphylococcus spp., or E. coli.\n                     \n                        Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of Streptococcus spp. (\u03b1- and \u03b2-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae.\n                  \n                  \n                     Adult Patients only\n                  \n                  \n                     \n                        \n                           Helicobacter pylori Infection and Duodenal Ulcer Disease:\n                        \n                        \n                           Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole:\n                        Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.\n                        \n                           Dual therapy for H. pylori with lansoprazole:\n                        Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.\n                  \n                  \n                     Usage\n                     \n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "In Adults, 750 to 1750 mg/day in divided doses every 8 to 12 hours. In Pediatric Patients over 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to 12 hours. Refer to full prescribing information for specific dosing regimens. ( 2.2 , 2.3 ) The upper dose for neonates and infants aged 3 months or younger is 30 mg/kg/day divided every 12 hours. ( 2.3 ) Dosing for H. pylori Infection (in Adults): Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. ( 2.4 ) Reduce the dose in patients with severe renal impairment (GFR greater than 30 mL/min). ( 2.5 )",
    "warningsAndPrecautions_original": "Amoxicillin tablets, USP:\n                  \n                  \n                     500 mg: Each tablet contains 500 mg of amoxicillin, USP as the trihydrate. Each film-coated, capsule-shaped, off-white, tablet is debossed with \u201c93\u201d on one side and \u201c2263\u201d on the other side. They are available in bottles of 100 (NDC 0093-2263-01) tablets.\n                  \n                     875 mg: Each tablet contains 875 mg of amoxicillin, USP as the trihydrate. Each film-coated, capsule-shaped, off-white tablet is scored on one side, debossed with \u201c93\u201d on one side of the score and \u201c2264\u201d on the other side of the score. They are available in bottles of 100 (NDC 0093-2264-01) tablets.\n                  \n                     Amoxicillin for oral suspension, USP: \n                  \n                     200 mg/5 mL: \u00a0Each 5 mL of reconstituted pink, fruit gum flavored suspension contains 200 mg amoxicillin, USP as the trihydrate. It is available in bottles of 50 mL (NDC 0093-4160-76), 75 mL (NDC 0093-4160-78), and 100 mL (NDC 0093-4160-73).\n                  \n                     250 mg/5 mL: \u00a0Each 5 mL of reconstituted mixed berry flavored suspension contains 250 mg amoxicillin, USP as the trihydrate. It is available in bottles of 80 mL (NDC 0093-4155-79), 100 mL (NDC 0093-4155-73), and 150 mL (NDC 0093-4155-80).\n                  \n                     400 mg/5 mL: \u00a0Each 5 mL of reconstituted pink, fruit gum flavored suspension contains 400 mg amoxicillin, USP as the trihydrate. It is available in bottles of 50 mL (NDC 0093-4161-76), 75 mL (NDC 0093-4161-78), and 100 mL (NDC 0093-4161-73).\n                  \n                     Amoxicillin Tablets (Chewable), USP:\n                  \n                  \n                     125 mg: \u00a0\u00a0Each white to off-white, capsule-shaped tablet, debossed 93 on one side and 2267 on the other side and contain 125 mg amoxicillin, USP as the trihydrate. They are available in bottles of 100 tablets (NDC 0093-2267-01).\n                  \n                     250 mg: \u00a0\u00a0Each white to off-white, capsule-shaped tablet, debossed 93 (partial bisect between 9 and 3) on one side and 2268 on the other side and contain 250 mg amoxicillin, USP as the trihydrate. They are available in bottles of 100 tablets (NDC 0093-2268-01).\n                  \n                     Amoxicillin Capsules, USP \n                  \n                  \n                     250 mg: Opaque caramel cap and opaque buff body, hard gelatin capsule. Printed black \u201cTEVA\u201d on cap and \u201c3107\u201d on body portions of the capsule and contain 250 mg amoxicillin, USP as the trihydrate. They are available in bottles of 100 (NDC 0093-3107-01) and 500 (NDC 0093-3107-05) capsules.\n                  \n                     500 mg: Opaque buff cap and opaque buff body, hard gelatin capsules. Printed black \u201cTEVA\u201d on cap and \u201c3109\u201d on body portions of the capsules and contain 500 mg amoxicillin, USP as the trihydrate. They are available in bottles of 50 (NDC 0093-3109-53), 60 (NDC 0093-3109-06), 100 (NDC 0093-3109-01) and 500 (NDC 0093-3109-05) capsules.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other \u03b2-lactam antibacterial drugs (e.g., penicillins and cephalosporins).",
    "drug": [
        {
            "name": "Amoxicillin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ]
}